Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-25
DOI
10.3389/fimmu.2020.01956
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
- (2020) Junling Zhuang et al. Thoracic Cancer
- Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
- (2020) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
- (2020) Arndt Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
- (2020) Chi-Jung Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
- (2020) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
- (2020) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.
- (2020) Sophie Cousin et al. JOURNAL OF CLINICAL ONCOLOGY
- Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China.
- (2020) Miaomiao Gou et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
- (2019) Shweta Joshi et al. Journal of Oncology
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Pancreatic adenocarcinomas with mature blood vessels have better overall survival
- (2019) Eriko Katsuta et al. Scientific Reports
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
- (2019) Kirstin Perdrizet et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).
- (2019) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Tumor Heterogeneity on FDG PET/CT and Immunotherapy: An Imaging Biomarker for Predicting Treatment Response in Patients With Metastatic Melanoma
- (2019) Y. Sanli et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- VEGF Impairs the Motility and Immune Function of Human Mature Dendritic Cells through VEGFR 2‐RhoA‐Cofilin1 Pathway
- (2019) Jinhua Long et al. CANCER SCIENCE
- ACORN: An observational study of bevacizumab in combination with first-line chemotherapy for treatment of metastatic colorectal cancer in the UK
- (2019) Shelize Khakoo et al. Clinical Colorectal Cancer
- 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
- (2019) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Recent advances in the clinical development of immune checkpoint blockade therapy
- (2019) Atefeh Ghahremanloo et al. CELLULAR ONCOLOGY
- Extensive stage small cell lung cancer with sustained complete response to single agent nivolumab and immune-related dermatitis
- (2019) Page Widick et al. Clinical Lung Cancer
- Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
- (2019) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody
- (2019) Ryota Shibaki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2019) B. Han et al. Journal of Thoracic Oncology
- Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
- (2019) Elaine R. Mardis Genome Medicine
- Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
- (2019) Vaishali Aggarwal et al. Biomolecules
- Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma
- (2019) Svetomir N. Markovic et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
- (2019) Motohide Uemura et al. CANCER SCIENCE
- Severe depletion of peripheral blood dendritic cell subsets in obstructive sleep apnea patients: A new link with cancer?
- (2019) Domenico Galati et al. CYTOKINE
- CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
- (2019) Xichen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
- (2019) Sara Elena Rebuzzi et al. Translational Cancer Research
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Immunotherapy-based combinations
- (2018) Giovanni Fucà et al. CURRENT OPINION IN ONCOLOGY
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
- (2018) Eric Jonasch et al. JOURNAL OF CLINICAL ONCOLOGY
- Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2018) Xinyang Liu et al. Journal of Hematology & Oncology
- Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma
- (2018) M. Pilar Laguna JOURNAL OF UROLOGY
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- (2018) Rindert Missiaen et al. SEMINARS IN CANCER BIOLOGY
- The dark side of tumor-associated endothelial cells
- (2018) Francesco De Sanctis et al. SEMINARS IN IMMUNOLOGY
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
- (2018) Kristina Buder-Bakhaya et al. Frontiers in Immunology
- Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab
- (2018) Anusha Vakiti et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
- (2018) Xin Gao et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
- (2018) Stacey Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.
- (2018) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab and Platinum-Based Chemotherapy as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer: Phase 1 Cohorts From the KEYNOTE-021 Study
- (2018) Shirish M. Gadgeel et al. LUNG CANCER
- Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma
- (2018) Courtney S. Malo et al. Frontiers in Oncology
- LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
- (2018) B I Rini et al. ANNALS OF ONCOLOGY
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment
- (2018) Sindy Vrecko et al. Oncotarget
- Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
- (2018) Maria Georganaki et al. Frontiers in Immunology
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
- (2017) Moshe C. Ornstein et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.
- (2017) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).
- (2017) Ian Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2017) Xinyang Liu et al. Journal of Hematology & Oncology
- Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report
- (2017) Xiao Zhu et al. Journal of Neurosurgery-Pediatrics
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Microangiopathie thrombotique et cancer
- (2017) Rania Kheder El-Fekih et al. Nephrologie & Therapeutique
- Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
- (2017) Lei Qin et al. NEURORADIOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
- (2017) Gabriella Lupo et al. Frontiers in Pharmacology
- Integration of pro- and anti-angiogenic signals by endothelial cells
- (2017) Shideh Kazerounian et al. Journal of Cell Communication and Signaling
- Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer
- (2016) Corey J. Langer et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
- (2016) R.S. Herbst et al. ANNALS OF ONCOLOGY
- Ipilimumab and Bevacizumab in Glioblastoma
- (2016) T. Carter et al. CLINICAL ONCOLOGY
- The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
- (2016) Weilan Ye DEVELOPMENTAL CELL
- Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival
- (2016) Jan Budczies et al. GENES CHROMOSOMES & CANCER
- Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003.
- (2016) Arkadiusz Z. Dudek et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
- (2016) X. Wu et al. Cancer Immunology Research
- Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
- (2015) Domenico Galetta et al. Clinical Lung Cancer
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells
- (2015) Sara E. Martin del Campo et al. JOURNAL OF IMMUNOLOGY
- Immunosuppressive cells in tumor immune escape and metastasis
- (2015) Yang Liu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis
- (2015) Li Sun et al. MEDICAL ONCOLOGY
- Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
- (2015) Rafael Carretero et al. NATURE IMMUNOLOGY
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin
- (2015) Chakrapani Tripathi et al. Oncotarget
- Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
- (2014) F. Barlesi et al. ANNALS OF ONCOLOGY
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
- (2014) Sander Kelderman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
- (2014) Tai Hato et al. HEPATOLOGY
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
- (2014) N.A. Rizvi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
- (2014) Sandra S. McAllister et al. NATURE CELL BIOLOGY
- Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer
- (2014) Labib Imran Faruque et al. PLoS One
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Control of the Adaptive Immune Response by Tumor Vasculature
- (2014) Laetitia Mauge et al. Frontiers in Oncology
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
- (2013) Fausto Petrelli et al. Clinical Colorectal Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Fractalkine (CX3CL1) and Its Receptor CX3CR1 May Contribute to Increased Angiogenesis in Diabetic Placenta
- (2013) Dariusz Szukiewicz et al. MEDIATORS OF INFLAMMATION
- Combining two strategies to improve perfusion and drug delivery in solid tumors
- (2013) T. Stylianopoulos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis
- (2012) Isabella Kanzler et al. BASIC RESEARCH IN CARDIOLOGY
- Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
- (2012) Ligia Traldi Macedo et al. BMC CANCER
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
- (2012) Jeffrey A. Meyerhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?
- (2012) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Nitric Oxide–Producing Myeloid-Derived Suppressor Cells Inhibit Vascular E-Selectin Expression in Human Squamous Cell Carcinomas
- (2012) Ahmed E. Gehad et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation
- (2011) S. Delfortrie et al. CANCER RESEARCH
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)
- (2011) Janessa Laskin et al. Journal of Thoracic Oncology
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization and Regulation of Bv8 in Human Blood Cells
- (2009) C. Zhong et al. CLINICAL CANCER RESEARCH
- Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions
- (2009) Jennifer K. Mulligan et al. HUMAN IMMUNOLOGY
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
- (2009) Christina L. Roland et al. PLoS One
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- (2008) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
- (2007) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started